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: The repertoire of thymic neuroendocrine precursors plays a dual
role in T-cell differentiation as the source of either cryptocrine accessory sig-
nals in T-cell development or neuroendocrine self-antigens presented by the
thymic major histocompatibility complex (MHC) machinery. Thymic neu-
roendocrine self-antigens usually correspond to peptide sequences highly con-
served during the evolution of one family. The thymic presentation of some
neuroendocrine self-antigens is not restricted by MHC alleles. Oxytocin (OT)
is the dominant peptide of the neurohypophysial family. It is expressed by thy-
mic epithelial and nurse cells (TEC/TNCs) of different species. Ontogenetic
studies have shown that the thymic expression of the OT gene precedes the




and other focal adhesion-related proteins in murine immature T cells. These
early cell activation events could play a role in the promotion of close interac-
tions between thymic stromal cells and developing T cells. It is established that
such interactions are fundamental for the progression of thymic T-cell differ-
entiation. Insulin-like growth factor 2 (IGF-2) is the dominant thymic polypep-
tide of the insulin family. Using fetal thymic organ cultures (FTOCs), the
inhibition of thymic IGF-2-mediated signaling was shown to block the early
stages of T-cell differentiation. The treatment of FTOCs with an mAb anti-
(pro)insulin had no effect on T-cell development. In an animal model of
autoimmune type 1 diabetes (BB rat), thymic levels of (pro)insulin and IGF-1
mRNAs were normal both in diabetes-resistant and diabetes-prone BB rats.
IGF-2 transcripts were clearly identified in all thymuses from diabetes-
resistant adult (5-week) and young (2- and 5-days) BB rats. In marked con-





80% of the thymuses from diabetes-prone adult and young
BB rats. These data show that a defect of the thymic IGF-2–mediated tolero-
genic function might play an important role in the pathophysiology of autoim-
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THE DUAL ROLE OF THYMIC NEUROENDOCRINE 
SELF-ANTIGENS IN T-CELL DIFFERENTIATION
 
Before reacting against “non-self” infectious agents, the immune system must be
able to tolerate the host molecular structure (“self”). The induction of immune self-
tolerance is a multistep process that is initiated inside the thymus during fetal ontog-









 The thymus is the primary lymphoid





 Our experimental studies since 1985 have established that the thymus
also constitutes one privileged meeting point between the two major systems of





parenchyme is the site of synthesis for protein precursors belonging to various neu-
roendocrine families. Thymic precursors not only provide accessory signals for
T-cell growth and development, but they are also the source of neuroendocrine self-





 the intrathymic presentation of neuroendocrine self-
antigens would induce the clonal deletion or developmental arrest of self-reactive T
cells. Such self-reactive T cells randomly emerge during the recombination of gene
segments coding for the chains of the T-cell receptor of antigen (TCR) and they are
bearing one TCR specifically directed toward the complex CMH/self-antigen. The
thymus is the major, if not the only one, lymphoid organ wherein permanently occurs
a confrontation between the presentation of the self molecular structure and a pure
random phenomenon with a potential toxic threat for the host organism. In physio-
logical conditions, this confrontation leads to the deletion or the inactivation of such
self-oriented toxicity. Even if other tolerizing mechanisms exist in the periphery, it
is now well established that the thymus exerts the dominant tolerogenic control upon
the immune system.
According to its nature as the source of either cryptocrine accessory signals or
self-antigens, respectively, the thymic repertoire of neuroendocrine precursors reca-
pitulates at the molecular level the dual physiological role of the thymus in T-cell
positive and negative selection. The interaction of neuroendocrine self-antigens with








M), but with a high selectivity. On the other hand, cryptocrine signaling between thy-
mic neuroendocrine-related peptides and their cognate neuroendocrine-type recep-












 Moreover, a hierarchy of dominance and an eco-
nomical principle appear in the organization of the polypeptide repertoire expressed
in the thymus. This is of high significance since self-tolerance primarily concerns




 This model concurs with the
“avidity/affinity hypothesis” that has been proposed as another explanation of the




 According to this latter hypothesis, T lym-





 M), and are deleted if TCR is strongly engaged with self-




 M). However, since the affinity of a TCR for its








 the intrathymic concen-
tration of self-peptides is of crucial importance for determining positive or negative
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T-cell selection. It therefore became a primary objective to define the nature and the




 to positive or negative
selection of a particular TCR in a normal thymus.
 
ONTOGENY OF THYMIC OT AND IGF GENE EXPRESSION
 
Although the two neurohypophysial genes, OT and vasopressin (VP), are




 at the peptide level OT is the dominant





 hybridization, and immunocytochemistry (ICC), we recently inves-
tigated the ontogeny of neurohypophysial gene expression in the thymus of Balb/c








 are detected without any visible modulation
in the thymus already from fetal day (FD) 14 until day 7 after birth. In the murine
thymus, neurohypophysial transcripts are located in cells with an epithelial morphol-




 Because of the microscopic size
of thymic rudiments before FD 14, it was not possible to analyze earlier the thymic





 shows that the transcription of neurohypophysial genes in the rodent
thymus precedes their expression in the magnocellular neurons of the hypothalamic–
neurohypophysial axis. At the peptide level, this difference is more evident since
ir-OT is detected in the thymus on FD 15, whereas ICC labels ir-OT in the hypothal-




 Thus, the expression of neurohypophysial genes in the
murine thymus coincides with the appearance of T-cell progenitors and slightly pre-
cedes their hypothalamic transcription. This observation is highly significant with
regard to the physiological role proposed for thymic OT both in T-cell lymphopoiesis
and in central tolerance of the hypothalamo-neurohypophysial functions. The early
expression of thymic OT is another experimental argument supporting a tolerogenic
role of the thymic repertoire of neuroendocrine self-antigen precursors. Indeed, it is
logical that the induction of central self-tolerance precedes the appearance of anti-




Furthermore, the putative thymic deletion of OT-reactive T-cell clones will allow the
immunomodulation by peripheral OT without the risk of inducing an autoimmune
hypothalamitis. For example, a non-specific immune activation is usually observed
in the postpartum, a period characterized by an increase of lactatory hormones (pro-
lactin and OT) and an enhancement of the estrogen/progesterone ratio.
The components of the IGF axis have also been characterized in the human thy-
mus. Human TEC expresses different members of this axis, with a predominance of




 In the human and rat thymuses,





RT-PCR analyses of total RNA from murine fetal and postnatal
thymuses revealed that IGF-1, IGF-2, IGF type 1 (IGF-1R) and type 2 (mannose-6-
phosphate [M6P]/IGF-2R) receptors are expressed from FD 14 through seven weeks
of age. Though RT-PCR conditions are not quantitative, a striking difference
appeared between the IGF-2 signals and the others studied. Similar mRNA levels of
IGF-1, IGF-1R, and M6P/IGF-2R were detected in all the fetal and postnatal murine
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were detected mainly in the epithelial component of the murine thymus. Therefore,
the expression of insulin-related genes in the thymus also precedes their peripheral
transcription, as in the pancreatic islet cells.
 
THE ROLE OF THYMIC OT AND IGF IN T-CELL DEVELOPMENT
 
After their migration from the fetal liver and then from bone marrow, immature
T-cell progenitors receive from the thymic parenchyme various types of signals
which regulate their differentiation program toward T-cell death or development.
These signals are not strictly thymus-specific, but their local action is linked to their
expression within a particular microenvironment and at a crucial step of T-cell dif-
ferentiation. The ability of pre-T cells to respond to thymic OT and IGF-2 was dem-
onstrated by a series of different approaches.
Functional neurohypophysial hormone receptors are expressed by immature T




 These lymphocyte receptors are different
from classic V1a/V2 receptors, and rather appear such as another V1 (V1b or V3?)




 They are able to transduce OT and VP into a
phospho-inositide turnover, and to mediate mitogenic effects of neurohypophysial-




 Moreover, in a line of pre-
T cells derived from a murine thymic lymphoma (RL12-NP), OT and VP quickly




, a tyrosine-kinase involved in focal adhe-














 As demonstrated by others,













 in RL12-NP cells suggests that thymic OT intervenes in T-cell selec-
tion, either as a promoter of focal adhesion itself, or as an anti-apoptotic inducer of
a cryptocrine signaling between TEC and T cells leading to the proliferation and sur-
vival of early T-cell precursors.
There is increasing evidence that IGFs are implicated in the development and
modulation of the immune response. Thymocytes express both types of IGF recep-




 Administration of IGF-1 stimulates thymus
and spleen growth and T-cell proliferation and development and modulates the




In addition, the thymus of IGF-2 transgenic mice contains high levels of IGF-2








 We also examined the role of IGFs on murine T-cell development by
evaluating the effect of anti-IGFs and IGF-receptors neutralizing Abs on the gener-





anti-IGF-1 nor anti-IGF-2 induced a significant change in the total cell number or
the percentage of dead cells as measured by propidium iodide staining. FTOC treat-
ment with anti-IGF-2 mAb, an anti-IGF-1R mAb, or an anti-M6P/IGF-2R poly-

























 cells. In addition, the treatment
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 stage as shown
by a decrease in single positive subsets. Moreover, anti-IGF-2 Ab treatment induced




 single positive cells, suggesting that thymic IGF-2 has a role in
determining differentiation into the CD4 or CD8 lineage. The total percentage of
viable cells was not affected by any of the anti-IGF-R Abs tested. However, in




 decrease in the total cell number.




) with the FTOC treatment by anti-IGF-1R.





with a specific anti-(pro)insulin mAb were unaffected neither in total cell number,




THYMIC PRESENTATION OF NEUROENDOCRINE SELF-ANTIGENS
 
The synthesis of OT in TEC/TNCs is not coupled to the classic secretion of the non-
apeptide and its precursor-associated binding neurophysin in the supernatant of TEC
primary cultures. In the murine thymus, ir-OT is not located in secretory granules, but
is diffuse in the cytosol, in vesicles of the endoplasmic reticulum, and in close associ-




 Similar ultrastructural features have also been




Those independent observations repeatedly questioned the classic model of neurose-
cretion which was established for OT and VP in the hypothalamo-neurohypophysial
tractus. They further suggested a processing of the OT precursor that differs in the thy-
mus compared to the situation in the hypothalamo-neurohypophysial axons. As dis-
cussed above, the thymic function is associated with the presentation of self-antigens
to developing T cells. This action was long thought to be mediated by thymic macroph-
ages and dendritic/interdigitating (IDC) cells only, but TEC/TNCs also are actively




 Thus, we hypothesized a pro-
cessing of thymic proOT that could be related to antigen presentation instead of a clas-
sic neurosecretion. 
 
Using affinity-chromatography with a mAb directed against the monomorphic




 we identified in TEC/TNC plasma mem-





 Since anti-neurophysin Abs do not cross-react with either






-microglobulin, this 55-kDa membrane protein
may represent a hybrid protein including both a neurophysin domain (10 kDa) and
an MHC class I heavy chain-related domain (45 kDa). The precise biochemical
mechanisms underlying the formation of this hybrid neurohypophysial/MHC class I
membrane protein are still to be further deciphered. Some preliminary hypotheses
may be advanced, however. The origin of this protein could reside at the posttran-




-splicing phenomenon) or at the posttranslational
level (such as the ATP-dependent binding of ubiquitin to protein targeted to proteol-
ysis). Following this putative explanation, the MHC class I domain would be impli-
cated in membrane targeting of this hybrid protein, whereas neurophysin binds
OT for presentation to pre-T cells. Other authors have shown the translocation of
a 45-kDa neurophysin-like material in the cell membranes of cancer cells, and have
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 Thus, both in the hypothalamo–neuro-
hypophysial axis and in the thymus, the neurophysin part of the OT precursor fulfills
the same function: binding of the active nonapeptide OT and tranport to the external
limits of neurons or TEC/TNCs. The tyrosine residue in position 2 of OT and VP




 Interestingly, the tyrosine
residue in the same position plays a crucial role in the binding of antigens to some




 The particular features of thymic OT-
mediated T-cell education to the neurohypophysial family can be related to the
observation of a dissociation between thymic T-cell education to self and peripheral




 Selective advantages appear from this model of thy-
mic neuroendocrine–self-antigen presentation. A first advantage is the absence of a
tight allelic restriction in thymic T-cell education to a neuroendocrine family. Such
an allelic restriction of central T-cell tolerance was hardly conceivable and our data
indicate that it is not the case in reality. Concerning the presentation of thymic OT,
though MHC class I molecules are involved in the process, it is the invariant neuro-
physin domain of the hybrid membrane 55-kDa protein that binds OT for presenta-
tion to pre-T cells. Another advantage resides in the presentation to pre-T cells of the
structure characteristic of the neurohypophysial family.
The antigenic behavior of thymic OT was further demonstrated by another type
of experiments. The immunological recognition of OT by specific mAbs at the outer
surface of human TEC plasma membrane induced a marked secretion of the cytok-





 Given the nature of the epitopes recognized by anti-OT mAbs, we could
conclude that the molecule OT is fully processed at the level of the TEC plasma
membrane. The absence of biological effects following the treatment of TEC cul-
tures with anti-VP mAbs further confirms that thymic OT behaves as the self-antigen
representative of the neurohypophysial hormone family.
Neurotensin (NT) and somatostatin have been extracted from the chicken thymus,





 Ir-NT is expressed at the cell surface of human TEC, and












 is associated with
plasma cell membranes. HPLC analysis of ir-NT present in human TEC revealed a




. Using an affinity column pre-
pared with the same anti-MHC class I Ab, NT-related peptides were retained on the




 With regard to the
thymic presentation of NT, there is no physical constraint for a non-covalent binding
to MHC since this neuropeptide is a linear peptide (in contrast to cyclic OT and
IGF-2). In addition, the C-terminal sequence of NT includes tyrosine, isoleucine and
leucine residues, which can all be used in the anchorage to most of the MHC class I
alleles. Given these characteristics, it is logical to postulate that NT and NT-derived
C-terminal fragments could behave as natural ligands for a majority (if not all) of
MHC class I alleles. This hypothesis is also in agreement with the high degree of




Neurokinin A (NKA) is the peptide of the tachykinin family encoded in human









appears to be glucocorticoid-dependent since adrenalectomy of Sprague-Dawley
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and Geenen, unpublished observations). Interestingly, NKA exerts IL-1-like mitoge-




 suggesting that tachykinin receptors are
expressed by immature T cells and are implicated as an accessory pathway in T-cell
maturation and positive selection. The amino-acid sequence of NKA shares the same
C-terminal epitope with other members of the tachykinin family, and the leucine res-
idue in position 9 could be used in the binding to some MHC class I alleles, thus





 substance P (SP), is not detected in TEC, but is present in sensory




 Thymic-specific receptors for SP are associated with





For IGFs, the role of binding and transport proteins is ensured by IGFBPs.
IGFBPs have co-evolved with IGFs, but are not intrinsic part of IGF precursors, and
are encoded by distinct genes. These proteins play a prominent role in regulating the




 Interestingly, some IGFBPs are in close
relationship with cell plasma membranes (through binding to integrins or the extra-
cellular matrix), but their relationship with MHC as well as their potential implica-
tion in thymic IGF presentation to immature T cells deserves to be further
investigated.
 
A DEFECT OF THYMIC FUNCTION IN 
AUTOIMMUNE TYPE 1 DIABETES
 
The development of an autoimmune disease affecting the neuroendocrine system
may be viewed as a failure to develop or to maintain self-tolerance of cellular and
molecular components which are constitutively expressed by neuroendocrine cells.
Three types of factors are usually thought to be implicated in the pathogeny of
autoimmune diseases: (1) The immune effectors are CD4 and CD8 auto-reactive T
cells which are specifically oriented against a given target cell or molecule. These
auto-reactive T cells are usually thought to result from a spontaneous breakdown of
peripheral T-cell tolerance. (2) A series of extra- and intra-MHC genes are related to
different autoimmune diseases. Some of these genes intervene in the presentation of
target auto-antigens to auto-reactive T lymphocytes, but others certainly not. (3) An
environmental factor is involved and establishes a link between the target auto-anti-
gens and auto-reactive T cells. A molecular mimicry between target auto-antigens




 The involvement of





Although the relationship between lymphoepithelial structures and autoimmunity




 the question of a defective cen-
tral T-cell self-tolerance in the pathophysiology of autoimmune diseases has
not been intensively investigated. Also, Burnet repeatedly proposed that the emer-
gence of “forbidden” self-reactive T-cell clones should play a major role in the
pathophysiology of autoimmunity. In this perspective, it has been shown that neona-
tal thymectomy prevents the emergence of diabetes in an animal model of auto-
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thymectomy usually induces a significant improvement in patients suffering from





 In both cases, the benefit of thymectomy can be
explained by the removal of the defective thymic censorship. Such a trouble in cen-
tral self-tolerance would be responsible for a continuous release and enrichment of
the peripheral T-cell pool with intolerant and self-reactive lymphocytes. The devel-
opment of diabetes is prevented by the transplantation of thymus from diabetes-




 The transplantation of the thymus from NOD





 While bone marrow transplantation is rather ineffective in preventing









 A defective process of thymic T-cell negative selection has been
suggested on the basis that the thymus of diabetes-resistant BB rats contains thy-




 Another argument is the observation that
grafts of pure thymic epithelium from NOD mouse embryos to newborn C57BL/6





histological level, a defect in thymic function could be linked to a disorganization of









 Recently, we exam-
ined the G75 elution profiles of ir-IGFs in the thymus from Wistar Furth (WF) nor-
mal rats and from diabetes-resistant and diabetes-prone BB rats. A peak of ir-IGF-2
above 10 ng/ml was observed in the G75 profile of WF thymus extracts; a peak
around 1.5 ng/ml was eluted from diabetes-resistant BB rat thymic extracts, however




transcripts were not detected by RT-PCR in the thymus of 11/15 diabetes-prone
BB rats, but were clearly identified in the thymus of 15/15 diabetes-resistant BB
rats. The defect of thymic IGF-2 expression was evidenced at different ages of the
diabetes-prone BB rat. The expression of proinsulin and IGF-1 genes was normal in
the thymus of diabetes-prone and diabetes-resistant BB rats. The defect of IGF-2
expression was tissue-specific since IGF-2 transcripts were detected in the brain and
liver of diabetes-prone BB rats.69 Taken together, these observations show a geneti-
cally determined defect of IGF2 expression in the thymus of diabetes-prone BB rats.
They also strongly support that a defect in the central T-cell self-tolerance of the
insulin family is involved in the pathophysiology of autoimmune type 1 diabetes, at
least in this animal model. A recent study has shown that the thymic and pancreatic
expression of IGF2 is not polymorphic enough to explain the human susceptibility
to type 1 diabetes, which is associated with IDDM2,70 the genetic locus that includes
the contiguous IGF2 and insulin genes. It must be pointed out, however, that the
imprinting of IGF2 could partially explain why the susceptibility to the disease is
higher in children from diabetic fathers than those from diabetic mothers.71,72
NEUROENDOCRINE SELF VERSUS AUTO-ANTIGENS
In the neurohypophysial family, the bulk of experimental data shows that OT is
the self-antigen of the neurohypophysial hormone family. A strong immunological
tolerance protects the OT lineage, more than the VP one, from an autoimmune
718 ANNALS NEW YORK ACADEMY OF SCIENCES
aggression. Indeed, some cases of so-called “idiopathic” central diabetes insipidus
result from an autoimmune hypothalamitis oriented toward VP-producing neurons.
Given the implication of the OT lineage at different levels of the reproductive pro-
cess, a stronger tolerance of this lineage is important for the preservation of the spe-
cies. Thus, in the neurohypophysial family, while OT behaves as the self-antigen, VP
is suspected to be the target auto-antigen of the autoimmune process. As discussed
previously, this conclusion is also supported by the frequences and the titers of Abs
induced by active immunization against neurohypophysial peptides (VP >> OT). An
infiltration of the hypothalamo-neurohypophysial tract by inflammatory mononucle-
ar cells can be observed, both after active immunization against VP,73 and in autoim-
mune “idiopathic” diabetes insipidus.17,18
FIGURE 1. The opposite immune responses elicited by the thymic presentation of a self-
antigen and the peripheral presentation of an auto-antigen. Thymic antigen-presenting cells
(APC) are thymic epithelial and nurse cells (TEC/TNC), macrophages and interdigitating cells
(IDC) or denditic cells. Neuroendocrine self-antigens correspond to peptide sequences of a
precursor that have been highly conserved during evolution of their corresponding family
(i.e., OT for the neurohypophysial peptides, IGF-2 for the insulin family, NKA for the tachy-
kinins). They are very homologous to peripheral related auto-antigens (i.e., VP for the neuro-
hypophysial peptides, insulin for the insulin family), although they are not identical. This
biochemical difference between neuroendocrine self- and auto-antigens results in opposite
immune responses with a deletion of self-reactive T-cell clones in the thymus (and anergy at
the periphery?), and an activation of auto-reactive T cells and induction of memory lympho-
cytes at the periphery.
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Insulin is one important auto-antigen tackled by various auto-reactive compo-
nents of the immune system both in animal and human type 1 diabetes.74,75 More-
over insulin is the specific marker of the pancreatic islet endocrine β cells. Oral,
intranasal and parenteral administration of insulin or insulin-derived dominant auto-
antigens have been shown to inhibit the occurrence of diabetes in animal models of
type 1 diabetes.76,77 However, one cannot exclude the risk of priming or triggering
autoimmunity by peripheral administration of an auto-antigen.78 Reprogramming
self-tolerance that has not been installed or that is broken in autoimmune diseases is
a very rational strategy for the prevention of devastating diseases such as multiple
sclerosis, rheumatoid arthritis or type 1 diabetes. Such reprogramming could be
based upon the tolerogenic properties of the thymic epithelium. Instead of the classic
immunogenic vaccination (with immune activation and induction of memory/immu-
nocompetent cells), the novel form of tolerogenic vaccination (or negative vaccine,
so to use the phrase proposed by Nossal)79 should provoke the deletion or the anergy
of auto-reactive T lymphocytes (FIG. 1). The induction of T-cell tolerance following
peptide vaccination has already been obtained with synthetic peptides representing
cytotoxic CD8 epitopes of T cells oriented against tumor antigens or viruses.80
According to Claude Bernard’s principles of experimental medicine, the hope
appears now that the correction of the defective central self-tolerance could prevent
the appearance of autoimmune type 1 diabetes. The tolerogenic vaccination repre-
sents a very attractive strategy for preventing autoimmune diseases, the heavy tribute
paid by the humans for the efficiency and complexity of their system of immune
defenses.
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